vs
Side-by-side financial comparison of Idexx Laboratories (IDXX) and Ventas (VTR). Click either name above to swap in a different company.
Ventas is the larger business by last-quarter revenue ($1.7B vs $1.1B, roughly 1.5× Idexx Laboratories). Idexx Laboratories runs the higher net margin — 22.8% vs 3.6%, a 19.2% gap on every dollar of revenue. On growth, Ventas posted the faster year-over-year revenue change (22.0% vs 14.3%). Over the past eight quarters, Ventas's revenue compounded faster (17.5% CAGR vs 6.4%).
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 by David Evans Shaw, the company is headquartered in Westbrook, Maine, and in Hoofddorp, Netherlands for its EMEA divisions.
Ventas is a leading real estate investment trust specializing in healthcare-related real estate assets. Its portfolio includes senior housing, medical offices, life science research facilities and rehabilitation centers, operating mainly across North America and the UK, serving healthcare operators and life science groups.
IDXX vs VTR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.7B |
| Net Profit | $248.2M | $59.0M |
| Gross Margin | 60.3% | — |
| Operating Margin | 28.9% | — |
| Net Margin | 22.8% | 3.6% |
| Revenue YoY | 14.3% | 22.0% |
| Net Profit YoY | 14.8% | 19.0% |
| EPS (diluted) | $3.09 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.7B | ||
| Q4 25 | $1.1B | $1.6B | ||
| Q3 25 | $1.1B | $1.5B | ||
| Q2 25 | $1.1B | $1.4B | ||
| Q1 25 | $998.4M | $1.4B | ||
| Q4 24 | $954.3M | $1.3B | ||
| Q3 24 | $975.5M | $1.2B | ||
| Q2 24 | $1.0B | $1.2B |
| Q1 26 | — | $59.0M | ||
| Q4 25 | $248.2M | $73.0M | ||
| Q3 25 | $274.6M | $68.7M | ||
| Q2 25 | $294.0M | $71.5M | ||
| Q1 25 | $242.7M | $48.4M | ||
| Q4 24 | $216.1M | $58.7M | ||
| Q3 24 | $232.8M | $21.0M | ||
| Q2 24 | $203.3M | $21.2M |
| Q1 26 | — | — | ||
| Q4 25 | 60.3% | — | ||
| Q3 25 | 61.8% | — | ||
| Q2 25 | 62.6% | — | ||
| Q1 25 | 62.4% | — | ||
| Q4 24 | 59.8% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 61.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 28.9% | 4.9% | ||
| Q3 25 | 32.1% | 3.0% | ||
| Q2 25 | 33.6% | 3.0% | ||
| Q1 25 | 31.7% | 3.0% | ||
| Q4 24 | 27.4% | -0.0% | ||
| Q3 24 | 31.2% | 1.5% | ||
| Q2 24 | 26.3% | -1.6% |
| Q1 26 | — | 3.6% | ||
| Q4 25 | 22.8% | 4.7% | ||
| Q3 25 | 24.8% | 4.6% | ||
| Q2 25 | 26.5% | 5.0% | ||
| Q1 25 | 24.3% | 3.6% | ||
| Q4 24 | 22.7% | 4.6% | ||
| Q3 24 | 23.9% | 1.7% | ||
| Q2 24 | 20.3% | 1.8% |
| Q1 26 | — | — | ||
| Q4 25 | $3.09 | $0.15 | ||
| Q3 25 | $3.40 | $0.14 | ||
| Q2 25 | $3.63 | $0.15 | ||
| Q1 25 | $2.96 | $0.10 | ||
| Q4 24 | $2.62 | $0.13 | ||
| Q3 24 | $2.80 | $0.05 | ||
| Q2 24 | $2.44 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $180.1M | $183.6M |
| Total DebtLower is stronger | $450.0M | — |
| Stockholders' EquityBook value | $1.6B | $13.2B |
| Total Assets | $3.4B | $27.7B |
| Debt / EquityLower = less leverage | 0.28× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $183.6M | ||
| Q4 25 | $180.1M | $741.1M | ||
| Q3 25 | $208.2M | $188.6M | ||
| Q2 25 | $164.6M | $614.2M | ||
| Q1 25 | $164.0M | $182.3M | ||
| Q4 24 | $288.3M | $897.9M | ||
| Q3 24 | $308.6M | $1.1B | ||
| Q2 24 | $401.6M | $557.1M |
| Q1 26 | — | — | ||
| Q4 25 | $450.0M | $13.0B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $617.8M | $13.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $13.2B | ||
| Q4 25 | $1.6B | $12.5B | ||
| Q3 25 | $1.6B | $12.4B | ||
| Q2 25 | $1.5B | $11.5B | ||
| Q1 25 | $1.4B | $11.5B | ||
| Q4 24 | $1.6B | $10.8B | ||
| Q3 24 | $1.6B | $9.8B | ||
| Q2 24 | $1.6B | $9.6B |
| Q1 26 | — | $27.7B | ||
| Q4 25 | $3.4B | $27.6B | ||
| Q3 25 | $3.4B | $26.9B | ||
| Q2 25 | $3.3B | $26.5B | ||
| Q1 25 | $3.2B | $26.0B | ||
| Q4 24 | $3.3B | $26.2B | ||
| Q3 24 | $3.4B | $25.3B | ||
| Q2 24 | $3.4B | $24.5B |
| Q1 26 | — | — | ||
| Q4 25 | 0.28× | 1.04× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.39× | 1.26× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $355.8M | — |
| Free Cash FlowOCF − Capex | $326.3M | — |
| FCF MarginFCF / Revenue | 29.9% | — |
| Capex IntensityCapex / Revenue | 2.7% | — |
| Cash ConversionOCF / Net Profit | 1.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.1B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $355.8M | $471.7M | ||
| Q3 25 | $402.3M | $378.6M | ||
| Q2 25 | $185.7M | $475.3M | ||
| Q1 25 | $238.0M | $321.1M | ||
| Q4 24 | $262.0M | $373.6M | ||
| Q3 24 | $220.1M | $353.7M | ||
| Q2 24 | $248.3M | $335.9M |
| Q1 26 | — | — | ||
| Q4 25 | $326.3M | — | ||
| Q3 25 | $371.2M | — | ||
| Q2 25 | $151.6M | — | ||
| Q1 25 | $207.9M | — | ||
| Q4 24 | $232.8M | — | ||
| Q3 24 | $192.0M | — | ||
| Q2 24 | $215.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 29.9% | — | ||
| Q3 25 | 33.6% | — | ||
| Q2 25 | 13.7% | — | ||
| Q1 25 | 20.8% | — | ||
| Q4 24 | 24.4% | — | ||
| Q3 24 | 19.7% | — | ||
| Q2 24 | 21.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 2.9% | — | ||
| Q2 24 | 3.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 6.46× | ||
| Q3 25 | 1.47× | 5.51× | ||
| Q2 25 | 0.63× | 6.65× | ||
| Q1 25 | 0.98× | 6.64× | ||
| Q4 24 | 1.21× | 6.36× | ||
| Q3 24 | 0.95× | 16.84× | ||
| Q2 24 | 1.22× | 15.87× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
VTR
| Resident fees and services | $1.3B | 78% |
| Outpatient medical and research portfolio | $230.1M | 14% |
| Triple-net leased properties | $123.1M | 7% |
| Third-party capital management revenues | $4.4M | 0% |
